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Neuropathic pain is a chronic condition that remains a major clinical problem owing
to high resistance to available therapy. Recent studies have indicated that chemokine
signaling pathways are crucial in the development of painful neuropathy; however, the
involvement of CC chemokine receptor 4 (CCR4) has not been fully elucidated thus far.
Therefore, the aim of our research was to investigate the role of CCR4 in the development
of tactile and thermal hypersensitivity, the effectiveness of morphine/buprenorphine,
and opioid-induced tolerance in mice exposed to chronic constriction injury (CCI) of
the sciatic nerve. The results of our research demonstrated that a single intrathecal or
intraperitoneal administration of C021, a CCR4 antagonist, dose dependently diminished
neuropathic pain-related behaviors in CCI-exposed mice. After sciatic nerve injury, the
spinal expression of CCL17 and CCL22 remained unchanged in contrast to that of
CCL2, which was significantly upregulated until day 14 after CCI. Importantly, our results
provide evidence that in naive mice, CCL2 may evoke pain-related behaviors through
CCR4 because its pronociceptive effects are diminished by C021. In CCI-exposed
mice, the pharmacological blockade of CCR4 enhanced the analgesic properties of
morphine/buprenorphine and delayed the development of morphine-induced tolerance,
which was associated with the silencing of IBA-1 activation in cells and decrease in CCL2
production. The obtained data suggest that the pharmacological blockade of CCR4 may
be a new potential therapeutic target for neuropathic pain polytherapy.
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INTRODUCTION
Neuropathic pain is associated with the dysfunction of or damage to the central or peripheral
nervous system. Despite many years of research in this field, the mechanism underlying the
generation and persistence of this type of pain is still not fully understood, and this has resulted
in a lack of appropriate and effective therapies. This is strictly due to the need for extended
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treatment, which results in an increased probability of side
effects (1). People suffering from neuropathic pain are afflicted
by impaired quality of life and continuous visits to health-care
providers. The management of painful neuropathy remains
challenging because opioids are less effective for neuropathic
pain than for other types of pain; therefore, it is necessary to
search for new, efficient, and long-acting analgesics (2). It was
recently suggested that the strong activation of non-neuronal
cells, especially microglia/macrophages, causes decreased
opioid-induced analgesic effects in neuropathic pain (3–6).
Pronociceptive cytokines (e.g., IL-1beta, IL-18, IL-6, CCL2,
and CCL5) released by these cells are considered important
factors responsible for reductions in opioid effectiveness
(7–11). Importantly, transmembrane cytokine receptors
expressed by neurons and microglia/macrophages are essential
for cell activation, which makes them promising targets
for pharmacological interventions (12). Recent studies have
indicated that the blockade of CC chemokine receptors (CCRs),
e.g., CCR2 and CCR5, attenuates neuropathic pain symptoms
(13–16). Considering that neuronal (17) and non-neuronal cells
(18, 19), including humanmicroglia/macrophage (20), have been
reported to express CCR4, we hypothesize that the blockade of
this receptor may serve as a new target for neuropathic pain
pharmacotherapy. CCR4 is a main receptor for CCL17 and
CCL22 (18, 21, 22), and its role in nociception has not been
studied in detail. It was previously suggested that CCL2 may also
act by binding with CCR4 (19). The pronociceptive properties of
CCL2 have already been described (23–25).
We hypothesize that CCR4 is important for nociceptive
processes in neuropathy; therefore, in the present paper, we
investigated the dose-dependent influence of a single intrathecal
(i.t.) or intraperitoneal (i.p.) administration of C021, a CCR4
antagonist, on tactile and thermal hypersensitivity in mouse
model of neuropathic pain. Additionally, we studied the changes
in the spinal expression of CCR4 potential ligands (CCL17,
CCL22, and CCL2) in mice following chronic constriction injury
(CCI) of the sciatic nerve. Moreover, the aim of this study was
to determine how the i.t. administration of C021 influences
tactile and thermal hypersensitivity evoked by CCL17, CCL22, or
CCL2 injection in naive animals. In a subsequent experiment, we
investigated whether a single administration of C021 influences
the analgesic effects of morphine and buprenorphine in CCI-
exposed rodents. Finally, we examined how repeated (twice daily
for 12 days) i.p. injection of C021 impacts the effectiveness
of chronically administered morphine and buprenorphine in
CCI-exposed mice. Moreover, we revealed changes in the
levels of IBA-1 (a microglia/macrophage activation marker),
GFAP (an astrocyte/satellite cell activation marker), and some
pronociceptive factors (CCL2, IL-1beta, IL-18, and iNOS).
MATERIALS AND METHODS
Animals
Male albino Swiss mice (20–22 g) were purchased from Charles
River (Hamburg, Germany) and housed in cages lined with
sawdust under a standard 12/12-h light/dark cycle (lights on at
06:00A.M.). Food and water were available ad-libitum. All of the
procedures were performed according to the recommendations
of the International Association for the Study of Pain (IASP)
(26) and the National Institutes of Health (NIH) Guide for
the Care and Use of Laboratory Animals. The study protocol
was approved by the II Local Ethics Committee branch of the
National Ethics Committee for Experiments on Animals based at
the Maj Institute of Pharmacology, Polish Academy of Sciences
(Krakow, Poland, LKE 75/2017, 1277/2015). Care was taken to
minimize animal suffering and reduce the number of animals
used in the experiments (3R policy).
Neuropathic Pain Model
Mice underwent CCI of the sciatic nerve under isoflurane
anesthesia according to the procedure described by Bennet and
Xie (27). An incision was made below the right hipbone, and the
biceps femoris and gluteus superficialis were separated. The right
sciatic nerve was exposed, and three ligatures (4/0 silk sutures)
spaced 1mm apart were tied loosely around the nerve distal to
the sciatic notch until a brief twitch was elicited in the respective
hind limb. CCI is a standard procedure that has been used in
our laboratory for many years to induce neuropathic pain-related
behaviors in rodents (15, 25, 28).
Behavioral Tests
Von Frey Test
Tactile hypersensitivity was measured using calibrated nylon
monofilaments (0.6–6 g) (Stoelting, Wood Dale, USA) to observe
reactions to mechanical stimuli, as described previously (25). The
mice were placed in plastic cages with a wire mesh floor 5min
before the experiment, and a von Frey filament was applied to the
midplantar surface of the hind paw until the hind paw was lifted.
In naive animals, both hind paws were tested in the same way.
Cold Plate Test
Thermal hypersensitivity was measured using a cold plate
analgesia meter (Ugo Basile, Gemonio, Italy) as described
previously (25). The temperature of the cold plate was kept at
2◦C. The cutoff latency was 30 s. The animals were placed on
the cold plate, and the latency until the hind paw was lifted was
recorded. In CCI-exposed mice, the injured foot was the first to
react to the cold stimulus in every case. In naive mice, both hind
paws were observed simultaneously.
Rotarod Test
The rotarod test is a commonly used method to measure motor
coordination in animals by assessing their ability to walk on a
rotating rod. This test was performed as previously described
(29). Mice were placed in a separate compartment on a rotating
horizontal rod that accelerated from 2 to 40 rpm within 300 s.
The animals were habituated to the apparatus and trained to
remain on the rotating rod. The main experiment was performed
after training sessions that each lasted 300 s. The rotarod test was
conducted 1 h after drug administration. When animals fall from
the apparatus, the time was recorded.
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Drug Administration
C021 dihydrochloride (C021; CCR4 antagonist; Tocris, Bristol,
UK); morphine hydrochloride [M; µ-opioid receptor (MOR),
δ-opioid receptor (DOR), and κ-opioid receptor (KOR)
agonist; TEVA, Kutno, Poland]; buprenorphine [B; MOR
and nociceptin receptor (NOR) agonist and DOR and KOR
antagonist; Polfa S.A., Warsaw, Poland], and recombinant mouse
CCL17/CCL22/CCL2 proteins (R&D Systems, Minneapolis,
USA) were dissolved in water for injection. The control groups
received water for injection (V) on the same schedule. The
substances were administered i.t. or i.p. The i.t. injections were
performed using a Hamilton syringe with a thin needle in
accordance with the literature (30). The substances were injected
into the lumbar part of the spinal cord (between the L5 and L6
vertebral space) in a volume of 5 µl. The i.p. injections were
performed in accordance with PolLASA (Polish Laboratory
Animal Science Association) guidelines.
1. C021 Administration in Chronic Constriction Injury-
Exposed Mice
The V or CCR4 antagonist was administered i.t. (10, 20, or
30 µg/5 µl) or i.p. (1, 5, 10, or 20 mg/kg) on day 7 after CCI.
Behavioral tests were conducted 1, 4, and 24 h after V or C021
injection. Day 7was chosen because this time point, in the used
model of neuropathy, is considered as a time when animals
fully develop thermal and mechanical hypersensitivity, which
relatively well-reflects human neuropathic pain symptoms
(27, 31–34).
2. Intrathecal CCL Administration Preceded by C021 Injection
in Naive Mice
The animals received a single i.t. injection of V or
C021 (30 µg/5 5l). Then, after 15min, V or recombinant
mouse CCL17/CCL22/CCL2 proteins (each 10 ng/5 µl)
were administered i.t. The behavioral tests were conducted
1, 4, and 24 h after the injection of the reconstituted
chemokines (i.e., 1 h 15min, 4 h 15min, and 24 h 15min
after V or C021 administration). The doses of recombinant
mouse CCL17/CCL22/CCL2 proteins were chosen based
on the dose–response curves published in our previous
papers (25, 35).
3. Single Coadministration of C021 and Opioids
The CCR4 antagonist was administered i.t. (30 µg/5
µl) or i.p. (5 mg/kg) on day 7 after CCI. Then, after
30min, the V- and C021-treated mice received a single
injection of morphine/buprenorphine (i.t., 1 µg/5 µl; i.p., 5
mg/kg). Behavioral assessments were conducted 30min after
opioid administration.
4. Repeated Coadministration of C021 and Opioids
In CCI-exposed mice, tolerance development was studied
administering morphine (30 mg/kg i.p.)/buprenorphine
(10 mg/kg i.p.) twice daily with or without C021 for
12 days starting from the first day after CCI. In the
experimental groups, C021 (5 mg/kg, i.p.) was administered
16 and 1 h before CCI and twice daily 30min before each
morphine/buprenorphine administration for the following
12 days. The control groups received V+V, C021+V,
V+M, or V+B on the same experimental schedule. The
behavioral tests were conducted every 2 days 30min after first
morphine/buprenorphine administration.
Analysis of Gene Expression (RT-qPCR)
Tissue from ipsilateral lumbar segments of the spinal cord
(L4–L6) was collected immediately after decapitation from naive
and CCI-exposed mice on days 2, 7, and 14 after sciatic nerve
injury for quantitative real-time PCR (RT-qPCR) analysis. Total
RNA extraction was performed using TRIzol reagent (Invitrogen,
Carlsbad, USA) on the basis of a previously described protocol
(36). The concentration and quality of RNA were measured by a
DeNovix DS-11 Spectrophotometer (DeNovix Inc., Wilmington,
USA). The Omniscript RT Kit (Qiagen Inc., Hilden, Germany),
oligo (dT16) primer (Qiagen Inc., Hilden, Germany), and
RNAse inhibitor (rRNasin, Promega, Mannheim, Germany)
were used for reverse transcription of 1 µg of total RNA.
The obtained cDNA was diluted 1:10 with RNase-/DNase-
free H2O. RT-qPCR was conducted with ∼50 ng of cDNA
from each sample using Assay-On-Demand TaqMan probes
(Applied Biosystems, Foster City, USA) on an iCycler device
(Bio-Rad, Hercules, Warsaw, Poland). The following TaqMan
primers were used: Mm03024075_m1 (hypoxanthine-guanine
phosphoribosyltransferase, HPRT); Mm01244826_g1 (CCL17);
Mm00436439_m1 (CCL22); and Mm00441243_g1 (CCL2).
Based on our previous study (25), HPRT was used as an
endogenous control and an adequate housekeeping gene. There
were no significant changes inHPRT expression between groups.
Analysis of Protein Levels
(Western Blotting)
Tissue from ipsilateral lumbar segments of the spinal cord (L4–
L6) was collected 6 h after the last V/C021 administration on
the 12th day of the experiment. The samples were homogenized
in radioimmunoprecipitation assay (RIPA) buffer containing
a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, USA)
and cleared via centrifugation (30min, 14,000 rpm, 4◦C). Total
protein concentrations were measured using the bicinchoninic
acid (BCA) method. Samples (10 µg of protein) were heated
in loading buffer (4 × Laemmli buffer, Bio-Rad, Warsaw,
Poland) for 5min at 98◦C. Electrophoresis was performed on
4–15% TGX precast polyacrylamide gels (Bio-Rad, Warsaw,
Poland). The proteins from the gels were transferred (semidry
transfer, 30min, 25V) to Immun-Blot polyvinylidene difluoride
(PVDF) membranes (Bio-Rad, Warsaw, Poland). Next, the
membranes were blocked for 1 h at room temperature using
5% nonfat dry milk (Bio-Rad, Warsaw, Poland) in Tris-buffered
saline with 0.1% Tween-20 (TBST). Then, the membranes were
washed in TBST buffer and incubated overnight at 4◦C with
the following primary antibodies: anti-IBA-1 (1:500, Novus,
Abingdon, UK); anti-GFAP (1:10000, Novus, Abingdon, UK);
rabbit anti-IL-1beta (1:500, Abcam, Cambridge, UK), anti-IL-18
(1:500, Abcam, Cambridge, UK), anti-iNOS (1:300, Proteintech,
Manchester, UK); and mouse anti-GAPDH (1:5,000, Millipore,
Darmstadt, Germany). Then, the membranes were washed in
TBST buffer and incubated for 1 h at room temperature in
horseradish peroxidase (HRP)-conjugated secondary antibodies
(Vector Laboratories, Burlingame, USA) at a dilution of 1:5,000.
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To dilute the primary and secondary antibodies, solution from
the SignalBoostTM Immunoreaction Enhancer Kit (Millipore,
Darmstadt, Germany) was used. Selected proteins were detected
using ClarityTM Western ECL Substrate (Bio-Rad, Warsaw,
Poland) and visualized by a Fujifilm LAS-4000 FluorImager
system. Fujifilm Multi Gauge software was used to estimate the
levels of the immunoreactive bands.
Analysis of Protein Levels (ELISA)
The CCL2 has low molecular weight; therefore, for detection,
the enzyme-linked immunosorbent assay (ELISA) method
was used. The samples were homogenized in RIPA buffer
containing a protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, USA) and cleared via centrifugation (30min, 14,000
rpm, 4◦C). ELISA for CCL2 was performed according to the
manufacturer’s instructions (mouse CCL2/MCP1 ELISA Kit,
LifeSpan Biosciences, Seattle, USA). The detection limit for CCL2
was 15.6–1,000 pg/ml. A positive control for the assay was
provided by the manufacturer.
Data Analysis
The behavioral and biochemical data are presented as the
mean ± SEM. To emphasize the overall impact and compare
effects from various behavioral tests, the area under the curve
(AUC) of antinociceptive effects was calculated. To evaluate the
AUCs, trapezoidal and Simpson’s rules were used as described
by Tallarida and Murray (37). The AUCs (1–12 days) were
calculated from the observed values (seconds for the cold plate
test and grams for the von Frey test). One-way analysis of
variance (ANOVA) was applied to evaluate the experimental
results, and Bonferroni’s post-hoc test was used to analyze the
differences between the groups. Additionally, some results were
evaluated using two-way ANOVA to determine the time ×
drug interaction.
RESULTS
The Influence of Single Intrathecal or
Intraperitoneal C021 Administration on
Neuropathic Pain-Related Behaviors
Measured on the Seventh Day After
Chronic Constriction Injury
Sciatic nerve injury evokes strong tactile and thermal
hypersensitivity in mice (p < 0.001, Figure 1). The i.t.
(Figures 1A,B) and i.p. (Figures 1C,D) C021 administration
dose dependently diminished tactile and thermal hypersensitivity
1, 4, and 24 h after treatment. In the von Frey test, the
i.t. administration of C021 at a dose of 30 µg/5 µl had
the most robust effect, significantly [F(4, 27) = 83.84, p <
0.0001] attenuating tactile hypersensitivity 1 h after injection
(Figure 1A). The i.p. administration of C021 at doses of 5,
10, and 20 mg/kg caused similar analgesic effects 1 h after
administration (Figure 1C). The observed effects lasted until
4 h after C021 administration. In the cold plate test, the i.t.
administration of C021 (30 µg/5 µl), compared with that of V,
the most significantly reduced thermal hypersensitivity [F(4, 25)
= 69, p < 0.0001] 1 h after injection (Figure 1B). The i.p. dose
that had the most robust effect on performance in the cold
plate test was 20 mg/kg, which led to the attenuation of thermal
hypersensitivity [F(5, 41) = 10.68, p < 0.0001] 1 h after injection
(Figure 1D). Analysis of the AUCs of the data obtained from the
behavioral tests confirmed that the i.t. (Figures 1E,F) and i.p.
(Figures 1G,H) administration of C021 to CCI-exposed mice
diminished the pain-related symptoms (Figures 1G,H).
Time-Dependent Study in the Spinal mRNA
Levels of CCL17, CCL22, and CCL2 in
Chronic Constriction Injury-Exposed Mice
In the von Frey test, we observed the development of strong
tactile hypersensitivity from the second to 14th days after CCI
(Figure 2A). In parallel, we did not observe any significant
changes in CCL17 (Figure 2B) and CCL22 (Figure 2C) mRNA
levels from the second to 14th days after CCI, which remained
at a constant low level of expression, compared with that of
naive mice. Nevertheless, we demonstrated that the CCL2 level
increased almost 19-fold 2 days after CCI [F(3, 33) = 11.37, p
< 0.0001] and 16-fold 7 days after CCI and then gradually
decreased; however, it was still significantly upregulated on day
14 (Figure 2D).
Effects of a Single Intrathecal
Administration of Recombinant CCL17,
CCL22, and CCL2 Proteins Preceded by
C021 Injection in Naive Mice
Our results indicated that a single i.t. administration of V and
C021 (30 µg/5 µl) had no effect on tactile hypersensitivity
at any of the examined time points, as measured by the
von Frey test (Figures 3B–D). Additionally, the results
presented as line graphs are in the Supplementary Materials
(Supplementary Figure 1). We observed strong tactile
hypersensitivity at 1 h after the administration of CCL17
[F3, 26 = 22.19, p < 0.0001] (Figure 3B), CCL22 [F(3, 26) = 91.63,
p < 0.0001] (Figure 3C), or CCL2 [F3, 24 = 22.82, p < 0.0001]
(Figure 3D) (each 10 ng/5 µl), and this effect was no longer
observed after 24 h, except in the case of CCL17 administration
[F3, 26 = 5.164, p = 0.0062]. C021 (30 µg/5 µl) administered
15min before the i.t. injection of recombinant CCL proteins
prevented chemokine-induced hypersensitivity in all examined
cases (Figures 3B–D).
Influence of a Single Intrathecal
Administration of C021 on the
Effectiveness of Morphine and
Buprenorphine on the Seventh Day After
Chronic Constriction Injury
Tactile and thermal hypersensitivity was observed in the von Frey
and cold plate tests 7 days after CCI (p < 0.0001, Figure 4). A
single i.t. injection of C021 (30 µg/5 µl), compared with that of
V, significantly attenuated CCI-induced tactile hypersensitivity,
as measured by the von Frey test (Figures 4B,D). Similarly,
in the cold plate test, we observed a reduction in thermal
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FIGURE 1 | The intrathecal or intraperitoneal administration of C021 (a CCR4 antagonist) dose dependently diminished hypersensitivity in CCI-exposed mice, as
measured by the von Frey and cold plate tests. The effects of a single i.t. (10, 20, or 30 µg/5 µl; A,B) or i.p. (1, 5, 10, or 20 mg/kg; C,D) injection of C021 7 days after
chronic constriction injury of the sciatic nerve on tactile (von Frey test; A,C) and thermal (cold plate test; B,D) hypersensitivity measured 1, 4, and 24 h following
antagonist administration. The data are presented as the mean ± SEM and the numbers of animals (shown as a n = mice tested in von Frey/n = mice tested in cold
plate) are as follows: i.t. N (n = 5/5) and CCI, V (n = 6/6), 10 (n = 6/6), 20 (n = 7/7), and 30 (n = 7/7); i.p. N (n = 5/5) and CCI, V (n = 6/6), 1 (n = 10/10), 5 (n =
10/10), 10 (n = 10/9), and 20 (n = 10/7). Additionally, the data obtained from von Frey (A,C) and cold plate (B,D) tests were analyzed as areas under the curve
(AUCs, E–H). The results were evaluated using one-way ANOVA followed by Bonferroni’s multiple comparisons post hoc test of selected pairs measured separately at
each time point. ooop < 0.001 indicates differences between naive and CCI-exposed mice (A–D) and all groups compared with naive mice (E–H). *p < 0.05, **p <
0.01, and ***p < 0.001 indicate significant differences between the V-treated and C021-treated CCI-exposed animals. Abbreviations: C021, C021 dihydrochloride;
CCI, chronic constriction injury; N, naive, V, vehicle. The dotted lines indicate the cutoff value for the tests.
hypersensitivity in C021-treatedmice (Figures 4C,E). Tactile and
thermal hypersensitivity were also significantly reduced after a
single i.t. administration of morphine (1 µg/5 µl) [F4, 29 = 39.53,
p < 0.0001] or buprenorphine (1 µg/5 µl) [F(4.31) = 43.03, p
< 0.0001], as measured by the von Frey test (Figures 4B,D)
and the cold plate test [morphine: F(4.22) = 58.43, p < 0.0001;
buprenorphine: F(4.25) = 47.49, p < 0.0001] (Figures 4C,E). We
observed that pretreatment with C021 potentiated the effects of
morphine in the von Frey test [F(4.29) = 39.53, p < 0.0001] and
cold plate test [F(4.22) = 58.43, p < 0.0001] (Figures 4B,C) and
increased buprenorphine-induced analgesia in both the von Frey
test [F(4.31) = 43.03, p < 0.0001] and cold plate test [F(4.25) =
47.49, p < 0.0001] (Figures 4D,E).
Influence of a Single Intraperitoneal
Administration of C021 on the
Effectiveness of Morphine and
Buprenorphine on the Seventh Day After
Chronic Constriction Injury
Tactile and thermal hypersensitivity was observed in the von
Frey and cold plate tests 7 days after CCI (p < 0.0001,
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FIGURE 2 | Neuropathic pain-related behaviors (A) appear in parallel with
spinal changes in the mRNA levels of CCL2 (D), but not CCL17 (B), or CCL22
(C), in (CCI)-exposed mice. Behavioral hypersensitivity was measured by the
von Frey test (A) 2, 7, and 14 days after injury. The behavioral data are
presented as the mean ± SEM; the numbers of animals are as follows: N (n =
10) and CCI, 2 days (n = 10), 7 days (n = 10), and 14 days (n = 10). The
RT-qPCR data are presented as the fold change relative to control (naive) mice
± SEM; the numbers of samples are as follows: N (n = 8–10) and CCI, 2 days
(n = 8), 7 days (n = 7–10), and 14 days (n = 8–9). The results were evaluated
using one-way ANOVA followed by Bonferroni’s multiple comparisons post hoc
test of selected pairs. ooop < 0.001 indicates differences compared with naive
mice. Abbreviations: C021, C021 dihydrochloride; CCI, chronic constriction
injury; N, naive; V, vehicle. The dotted line indicate the cutoff value for the test.
Figure 5). A single i.p. injection of C021 (5 mg/kg), compared
with that of V, significantly attenuated CCI-induced tactile
hypersensitivity 1 h after administration, as measured by the
von Frey test (Figures 5B,D); likewise, a reduction in thermal
hypersensitivity in the cold plate test (Figures 5C,E) was
observed. Hypersensitivity was also significantly diminished
after a single i.p. administration of morphine (5 mg/kg) or
buprenorphine (5 mg/kg), as measured by the von Frey test
[morphine: F(3, 25) = 23.79, p < 0.0001; buprenorphine: F(3, 25)
= 39.55, p < 0.0001] (Figures 5B,D) and the cold plate test
[morphine: F(3, 25) = 194.5, p < 0.0001; buprenorphine: F(3, 26)
= 72.16, p < 0.0001] (Figures 5C,E). The i.p. administration
of C021 enhanced the effectiveness of both morphine and
buprenorphine in the von Frey test [morphine: F3, 25 = 23.79,
p < 0.0001; buprenorphine: F(3, 25) = 39.55, p < 0.0001]
(Figures 5B,D) and cold plate test [morphine: F(3, 25) = 194.5,
p < 0.0001; buprenorphine: F(3, 26) = 72.16, p < 0.0001]
(Figures 5C,E).
Influence of Repeated Intraperitoneal
Administrations of C021 on the Analgesic
Effects of Chronic Treatment With
Morphine in Chronic Constriction
Injury-Exposed Mice
The behavioral results from naive and vehicle-treated CCI-
exposed mice clearly show that neuropathic animals’ reactivity
to mechanical and thermal stimuli is on a stable significant lower
level till 12 days (p < 0.0001; Figures 6B,C). Repeated morphine
treatment (twice daily; 30 mg/kg, i.p.) for 12 days (Figure 6A) led
to the development of morphine tolerance in CCI-exposed mice,
as measured by the von Frey test (Figure 6B). The analgesic effect
of morphine on day 5 was reduced compared with the effect of
morphine on the first day of the experiment; however, it was still
significantly stronger than that of V (Figure 6B). Pretreatment
with C021 followed by the 12-day administration of C021 (twice
daily, 5 mg/kg, i.p.) plus morphine (twice daily, 30 mg/kg, i.p.)
significantly improved the analgesic effects of this opioid, as
demonstrated by the von Frey test (Figure 6B). Additionally, the
injection of C021 alone attenuated the development of tactile
hypersensitivity in mice following CCI (Figure 6B). Similar
effects were observed in the cold plate test, in which the analgesic
effect of morphine on day 5 was reduced compared with to the
effect of morphine on the first day of the experiment; however,
it was still significantly stronger than that of V (Figure 6C).
Pretreatment with C021 followed by the 12-day coadministration
of C021 and morphine improved the analgesic effects of
morphine, as demonstrated by the cold plate test (Figure 6C).
Two-way ANOVA confirmed a significant interaction between
the investigated treatment and the considered time points in
the von Frey test [F(32, 432) = 11, p < 0.0001] and cold
plate test [F(32, 431) = 28.62, p < 0.0001]. Analysis of the
AUCs of the data obtained from behavioral tests confirmed
that the repeated coadministration of C021 and morphine
to CCI-exposed mice strongly enhanced the effectiveness of
morphine (Figures 6D,E). In parallel, we performed the rotarod
test to evaluate changes in the motor activity of the animals
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FIGURE 3 | The pronociceptive effect of a single intrathecal administration (10 ng/5 µl) of CCL17 (B), CCL22 (C), or CCL2 (D) is diminished by intrathecal
pretreatment with C021 (30 µg/5 µl) in naive mice. Behavioral tests were performed 1 h 15min, 4 h 15min, and 24 h 15min after C021 treatment; or 1, 4, and 24 h
after CCL administration (A). Tactile hypersensitivity (von Frey test) was measured (B–D). The data are presented as the mean ± SEM, the numbers of animals are as
follows: N (n = 5) and CCI, V+V (n = 6), V+CCL17 (n = 8), V+CCL22 (n = 8), V+CCL2 (n = 7), C021+V (n = 8), C021+CCL17 (n = 8), C021+CCL22 (n = 8), and
C021+CCL2 (n = 7–8); and the results were evaluated by one-way ANOVA followed by Bonferroni’s multiple comparisons post hoc test of selected pairs at
respective time points. *p < 0.05, **p < 0.01, and ***p < 0.001 indicate differences between the V+V-treated and V+CCL17/CCL22/CCL2-treated naive mice; ∧p <
0.05 and ∧ ∧ ∧p < 0.001 indicate differences between the V+CCL17/CCL22/CCL2-treated and C021+CCL17/CCL22/CCL2-treated naive mice. The dotted lines
indicate the naive value for the tests. Abbreviations: C021, C021 dihydrochloride; N, naive; V, vehicle.
after 12 days of administration (Figure 6F). The results of
our study revealed that the repeated administration of C021,
morphine, and C021 combined with morphine improved the
motor coordination of animals, whereas V-treatedmice exhibited
significant impairments in motor coordination [F(4, 54) = 5.384,
p= 0.0010] (Figure 6F).
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FIGURE 4 | A single intrathecal administration of C021 (CCR4 antagonist; 30
µg/5 µl) enhanced the effectiveness of morphine (1 µg/5 µl) and
buprenorphine (1 µg/5 µl) in CCI-exposed mice, as measured by the von Frey
(B,D) and cold plate (C,E) tests. Mice treated with a single administration of V
or C021 received a single dose of V, M, or B after 30min; and 30min later,
behavioral tests were conducted (A). The data are presented as the mean ±
SEM and the numbers of animals (shown as a n = mice tested in von Frey/n =
mice tested in cold plate) are as follows: N (n = 5/5) and CCI, V+V (n = 7/6),
C021+V (n = 7/7), V+M (n = 8/5), C021+M (n = 7/4), V+B (n = 8/7), and
C021+B (n = 8/7). The results were analyzed using one-way ANOVA with
Bonferroni’s multiple comparisons post hoc test. op < 0.05, oop < 0.01, ooop
< 0.001 indicate differences compared with naive mice; *p < 0.05, **p < 0.01,
and ***p < 0.001 compared with V+V-treated CCI-exposed mice; +p < 0.05
and +++p < 0.001 indicate differences between the V+M/B-treated and
C021+M/B-treated CCI-exposed mice; @@p < 0.01 and @@@p < 0.001
indicate differences between the C021+V-treated and C021+M/B-treated
CCI-exposed mice. The dotted lines indicate the cutoff value for the tests.
Abbreviations: B, buprenorphine; C021, C021 dihydrochloride; CCI, chronic
constriction injury; M, morphine; N, naive, V, vehicle.
FIGURE 5 | A single intraperitoneal administration of C021 (a CCR4
antagonist; 5 mg/kg) enhanced the effectiveness of morphine (5 mg/kg) and
buprenorphine (5 mg/kg) in CCI-exposed mice, as measured by the von Frey
(B,D) and cold plate (C,E) tests. Mice treated with a single administration of V
or C021 received a single dose of V, M, or B after 30min; and 30min later,
behavioral tests were conducted (A). The data are presented as the mean ±
SEM, and the numbers of animals (shown as a n = mice tested in von Frey/n
= mice tested in cold plate) are as follows: N (n = 5/5) and CCI: V+V (n =
7/7), C021+V (n = 8/8), V+M (n = 7/7), C021+M (n = 7/7), V+B (n = 7/7),
and C021+B (n = 8/8). The results were analyzed using one-way ANOVA with
Bonferroni’s multiple comparisons post hoc test. oop < 0.01, ooop < 0.001
indicate differences compared with naive mice; ***p < 0.001 compared with
V+V-treated CCI-exposed mice; ++p < 0.01 and +++p < 0.001 indicate
differences between the V+M/B-treated and C021+M/B-treated CCI-exposed
mice; @@@p < 0.001 indicates differences between the C021+V-treated and
C021+M/B-treated CCI-exposed mice. Abbreviations: B, buprenorphine;
C021, C021 dihydrochloride; CCI, chronic constriction injury; M, morphine; N,
naive, V, vehicle. The dotted lines indicate the cutoff value for the tests.
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Influence of Repeated Intraperitoneal
Administration of C021 on the Analgesic
Effects of Chronic Treatment With
Buprenorphine in Chronic Constriction
Injury-Exposed Mice
The behavioral results from naive and vehicle-treated CCI-
exposed mice clearly show that neuropathic animals’ reactivity
to mechanical and thermal stimuli is on a stable significant
lower level till 12 days (p < 0.0001; Figures 7B,C). Repeated
buprenorphine treatment (twice daily, 10 mg/kg i.p.) for 12 days
did not lead to the development of tolerance; however, a decrease
in the analgesic potency of buprenorphine was observed on day
5, as measured by the von Frey test (Figure 7B). Interestingly,
pretreatment with and repeated administrations of C021 (twice
daily, 5 mg/kg, i.p.) delayed the decrease in the effectiveness
of buprenorphine. The antinociceptive effects of buprenorphine
C021 and the coadministration of these substances were similar
from day 8 until the end of the experiment on day 12, and
these effects were significantly stronger than the effect of V,
as assessed by the von Frey test (Figure 7B). Similar effects
were observed in the cold plate test, in which the analgesic
effect of buprenorphine on day 5 was reduced compared with
the effect of buprenorphine on the first day; however, the
effect was still significantly higher than that of V (Figure 7C).
Pretreatment with C021 followed by the 12-day administration of
C021 (twice daily; 30 mg/kg, i.p.) combined with buprenorphine
significantly improved the analgesic effects of buprenorphine, as
demonstrated by the von Frey and cold plate tests (Figures 7B,C).
Two-way ANOVA confirmed a significant interaction between
the investigated treatment and the investigated time points in
the von Frey test [F(32, 430) = 4.951, p < 0.001] and cold plate
test [F(32, 433) = 8,998, p < 0.001]. Analysis of the AUCs of the
data obtained from the behavioral tests also showed that the
repeated administration of C021 together with buprenorphine to
CCI-exposed mice strongly influenced the analgesic properties
of buprenorphine (Figures 7D,E). Simultaneously, we conducted
the rotarod test to evaluate changes in the motor activity
of animals after 12 days of administration (Figure 7F). The
results of our study showed that the repeated administration of
C021, buprenorphine, and C021 combined with buprenorphine
improved the motor coordination of animals, whereas V-treated
mice exhibited significant impairments in motor coordination
[F4, 55 = 3.951, p= 0.0069] (Figure 7F).
Influence of the Repeated Intraperitoneal
Administration of C021 on the Protein
Levels of IBA-1, GFAP, IL-1beta, IL-18,
iNOS, and CCL2 in Chronic Constriction
Injury-Exposed Mice
Pretreatment with C021 followed by the 12-day administration
of C021 (twice daily, 5 mg/kg, i.p.) significantly diminished
the CCI-induced enhancement of the protein level of IBA-1
compared with that in the naive animals, as measured byWestern
blot analysis [F(2, 18) = 6.063, p = 0.0097] (Figure 8A). We
did not observe changes in GFAP levels on day 12 after CCI,
and C021 did not affect the level of this protein (Figure 8B).
Similarly, the protein levels of IL-1beta, IL-18, and iNOSwere not
affected after C021 administration (Figures 8C–E). Additionally,
the membranes for each Western blot analysis are presented
in the Supplementary Materials (Supplementary 2). Moreover,
pretreatment with C021 followed by the 12-day administration
of C021 diminished the CCI-induced enhancement of the level
of CCL2 in the spinal cords of CCI-exposed mice compared with
that in naive mice, as measured by ELISA [F(2, 30) = 3.52, p =
0.0424] (Figures 8F).
DISCUSSION
The results of our research demonstrated that a single i.t. or i.p.
administration of C021, a CCR4 antagonist, dose dependently
diminished neuropathic pain-related behaviors in CCI-exposed
mice. After sciatic nerve injury, the spinal levels of CCL17
and CCL22 remained unchanged, unlike the level of CCL2,
which was upregulated until day 14 after CCI. Importantly,
our results provide evidence that CCL2 may evoke pain-
related behaviors in naive mice through CCR4 because the
pronociceptive effects of CCL2 were diminished by a CCR4
antagonist. In CCI-exposed mice, the pharmacological blockade
of CCR4 enhanced the analgesic properties of morphine
and buprenorphine, delayed the development of morphine
tolerance, and improved the antinociceptive effects of chronically
administered buprenorphine. Our novel findings suggest that
C021 treatment prevented the increase in Iba-1 protein level and
probably and, as a consequence, diminished the level of CCL2.
The obtained results provide evidence that CCR4 may serve
as a potential therapeutic target for neuropathic pain therapy
or polytherapy.
CCR4 is expressed in the dorsal root ganglion (DRG) (38),
spinal cord (39), and brain (40) by neuronal (17) and non-
neuronal cells, for example, microglia, astroglia, Th2 cells,
dendritic cells, macrophages, natural killers, and platelets (18,
20). Its importance in the pathogenesis of diabetes (41), multiple
sclerosis (18), asthma (42), and dermatitis (43) was previously
described; however, the role of CCR4 in painful neuropathy has
not been studied so far. The first CCR4 ligand, CCL17 [thymus
and activation-regulated chemokine (TARC)] (22) might be
produced by not only thymus and peripheral blood mononuclear
cells but also dendritic cells (18) and neurons (44). It has
already been described that CCL17 levels are elevated in the
serum of patients suffering from fibromyalgia (45) and in the
cerebrospinal fluid of patients with multiple sclerosis (46) as
well as in dendritic cells in an animal model of experimental
autoimmune encephalomyelitis (47). Furthermore, recent studies
have indicated that the neutralization of CCL17, which is elevated
in the synovial fluid in a mouse model of osteoarthritis, relieves
pain (48). The secondCCR4 ligand, CCL22 [macrophage-derived
chemokine (MDC)], which shares 37% identity at the amino acid
level with CCL17 (21), is released by macrophages and serves as
a chemoattractant for T lymphocytes, NK cells, monocytes, and
dendritic cells (18, 49). CCL22 is considered to be upregulated
in the lungs of patients with allergic asthma (42) and in skin
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FIGURE 6 | Repeated twice daily intraperitoneal administration of C021 (CCR4 antagonist; 5 mg/kg) attenuated the development of morphine tolerance, as measured
by the von Frey (B,D) and cold plate (C,E) tests, and beneficially influenced motor coordination in CCI-exposed mice, as measured by the rotarod (F) test. V and
C021 were repeatedly administered i.p. 16 and 1 h before CCI and then twice daily for 12 days 30min before treatment with V or morphine (M, 30 mg/kg); and 30min
later, the behavioral tests were conducted (A). The data are presented as the mean ± SEM, and the numbers of animals (shown as n = mice tested in von Frey/n =
mice tested in cold plate) are as follows: N (n = 6/6) and CCI, V+V (n = 12/12), C021+V (n = 12/12), V+M (n = 11/11), and C021+M (n = 12/12). The results were
analyzed using one-way ANOVA with Bonferroni’s multiple comparisons post hoc test. Additionally, the results were evaluated using two-way ANOVA to determine the
time × drug interaction (Result part, page 10). Additionally, the data obtained from von Frey (D) and cold plate (E) tests were analyzed as areas under the curve
(AUCs). oop < 0.01, ooop < 0.001 indicate differences between naive and CCI-exposed mice (B,C,F) and all groups compared with naive mice (D,E); *p < 0.05, **p <
0.01, and ***p < 0.001 indicate differences compared with V+V-treated CCI-exposed mice; +p < 0.05 and +++p < 0.001 indicate differences between the
V+M-treated and C021+M-treated CCI-exposed mice; @p < 0.05 and @@@p < 0.001 indicate differences between the C021+V-treated and C021+M-treated
CCI-exposed mice. Abbreviations: C021, C021 dihydrochloride; CCI, chronic constriction injury; M, morphine; N, naive, V, vehicle. The dotted lines indicate the cutoff
value for the tests.
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FIGURE 7 | Repeated twice daily intraperitoneal administration of C021 (a CCR4 antagonist; 5 mg/kg) enhanced the analgesic properties of buprenorphine, as
measured by the von Frey (B,D) and cold plate (C,E) tests, and beneficially influenced motor coordination in CCI-exposed mice, as measured by the rotarod (F) test.
V and C021 were repeatedly administered i.p. 16 and 1 h before CCI and then twice daily for 12 days 30min before treatment with V or buprenorphine (B, 10 mg/kg);
and 30min later, the behavioral tests were conducted (A). The data are presented as the mean ± SEM, and the numbers of animals (shown as n = mice tested in von
Frey/n = mice tested in cold plate) are as follows: N (n = 6/6) and CCI, V+V (n = 12/12), C021+V (n = 12/12), V+B (n = 11/11), and C021+B (n = 12/12). The
results were analyzed using one-way ANOVA with Bonferroni’s multiple comparisons post hoc test. Additionally, the results were evaluated using two-way ANOVA to
determine the time × drug interaction (Result part, page 10). Additionally, the data obtained from von Frey (D) and cold plate (E) tests were analyzed as areas under
the curve (AUCs). oop < 0.01, ooop < 0.001 indicate differences between naive and CCI-exposed mice (B,C,F) and all groups compared with naive mice (D,E); *p <
0.05 and ***p < 0.001 indicate differences compared with V+V-treated CCI-exposed mice; +p < 0.05, ++p < 0.01, and +++p < 0.001 indicate differences
between the V+B-treated and C021+B-treated CCI-exposed mice; @p < 0.05, @@p < 0.01, and @@@p < 0.001 indicate differences between the C021+V-treated
and C021+B-treated CCI-exposed mice. Abbreviations: B, buprenorphine; C021, C021 dihydrochloride; CCI, chronic constriction injury; N, naive, V, vehicle. The
dotted lines indicate the cutoff value for the tests.
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FIGURE 8 | The intraperitoneal administration of C021 (a CCR4 antagonist; 5 mg/kg) influenced the spinal level of IBA-1 (A) and CCL2 (F), but not GFAP (B), IL-1beta
(C), IL-18 (D), or iNOS (E), in CCI-exposed mice, as measured by Western blotting (A–E) and ELISA (F). Lumbar segments of the spinal cord were collected after
repeated i.p. administration of C021 16 and 1 h before CCI and then twice daily for 12 days 6 h after the last administration. The data are presented as the mean ±
SEM from Western blot, and the numbers of samples are as follows: N (n = 7–8) and CCI, V+V (n = 7–8), and C021+V (n = 7–8); and ELISA, N (n = 12) and CCI,
V+V (n = 11) and C021+V (n = 10). The results were analyzed using one-way ANOVA with Bonferroni’s multiple comparisons post hoc test. op < 0.05 and oop <
0.01 indicate differences between the N and V+V-treated CCI-exposed mice; *p < 0.05 indicates differences between V+V-treated and C021+V-treated
CCI-exposed mice. Abbreviations: CCI, chronic constriction injury; N, naive; V, vehicle.
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lesions during dermatitis (43). As far as we know, there is
no information about the involvement of CCL17 and CCL22
in the pathogenesis of neuropathic pain. Under physiological
conditions, chemokines are constitutively expressed in nervous
system, however, usually on a very low level (14, 15). In the
present paper, we gave first evidence that after sciatic nerve injury
in mice, the spinal expression of CCL17 and CCL22 remains
unchanged compared with that of the control group. These
results are in agreement with our previous study showing that in
a rat model of neuropathic pain, there is a lack of spinal changes
in CCL17 and CCL22 mRNA levels after nerve injury (35). In
our pharmacological study, we provided evidence that the i.t.
injection of CCL17 and CCL22 caused pain-related behaviors in
naive mice, but the preinjection of a CCR4 antagonist inhibited
the pronociceptive effects of these chemokines. What is more,
CCL17 and CCL22 might also regulate peripheral nociceptive
processes, because their mRNA level is upregulated in DRGs, 7
days after sciatic nerve injury in rats (35). Here, we showed for
the first time that a single i.t. injection of C021, as well as a single
i.p. injection of C021, reduced hypersensitivity in neuropathic
mice. In the light of these biochemical and behavioral results, we
can hypothesize that i.p. administration of the C021 is effective
owing to ability to diminish the levels of pronociceptive CCL17
and CCL22 in DRG; however, this requires further study.
Based on recent reports, there are some hypotheses that
CCL2 [monocyte chemoattractant protein-1 (MCP-1)] may also
act through CCR4 (19). This agrees with our results showing
that the i.t. preinjection of a CCR4 antagonist can block the
pronociceptive properties of CCL2 in naive mice. Data in
the literature provide evidence that CCL2 is produced by a
variety of cell types, including fibroblasts and astrocytes, but
mainly by monocytes and microglial cells (50), and serves as
a chemoattractant for monocytes, T lymphocytes, and natural
killer cells (51). It has been shown that this chemokine
participates in the pathogenesis of various diseases, such as
multiple sclerosis (51), rheumatoid arthritis (52), and insulin-
resistant diabetes (53). Many studies have suggested that CCL2
plays a crucial role in neuropathic pain development at the spinal
cord and DRG level (14, 25, 54). Recent studies have revealed
an increase in CCL2 levels, which is associated with strong
spinal activation of glial cells and, consequently, the development
of neuropathic pain-related behaviors, after peripheral nerve
injury in different structures of the nervous system (24, 25,
55, 56). This is in agreement with our results showing strong
spinal mRNA upregulation of this chemokine from 2 to 14
days after sciatic nerve injury. Moreover, we observed alleviation
of pain-related behaviors, reduced activation of IBA-1 in cells,
and, likely as a consequence, decreased protein levels of CCL2
after repeated treatment with C021. Importantly, a single i.t.
administration of C021, a CCR4 antagonist, diminished fully
developed hypersensitivity after nerve injury, but this was not
the case for RS5043930, a CCR2 antagonist (14). Therefore,
we hypothesize that CCL2/CCR4 signaling at the spinal cord
level might be important in nociceptive transmission. Moreover,
taking into consideration our results and aforesaid literature,
all three chemokines acting via CCR4, that is, CCL17, CCL22,
and CCL2, seem to be important mediators in pathological
nociceptive processes at the DRG level under neuropathy (14,
35). Therefore, we assume that analgesic action of C021 might
be related with blockade of their pronociceptive effects in DRG,
which would explain why i.p. administration is so effective.
Despite many basic and clinical studies on the mechanisms
underlying neuropathic pain, this phenomenon has not been
fully elucidated, and thus, commonly used analgesics are not
sufficiently effective and cause many side effects (1). Opioids
are used as third-line drugs for the management of chronic
pain; however, their repeated and prolonged administration
results in the development of tolerance, leading to a progressive
reduction in their analgesic potency (1, 28, 57). It was previously
suggested that heterologous desensitization between opioid and
chemokine receptors might be one of the mechanisms that
contribute to increasing the efficacy of opioids in neuropathic
pain (11, 58). Changes in receptor conformation may have an
impact on receptor activation and/or ligand binding. There is
evidence showing that MOR and CCR5 can create heterodimers
(59, 60). The beneficial effects of maraviroc (a CCR5 antagonist)
on the effectiveness of opioids have already been shown in
rats with neuropathic pain (15). This suggests that chemokine
receptor antagonists may be used to support opioid therapy.
Our studies showed that a single i.t. or i.p. coadministration
of C021 and morphine (ligand of MOR, DOR, and KOR) or
buprenorphine (ligand of MOR, DOR, KOR, and NOR) resulted
in the potentiation of the analgesic properties of these opioids.
To our knowledge, there is no evidence that CCR4 can create
heterodimers with opioid receptors; nevertheless, further detailed
investigations are required. Another important reason for the
loss of the effectiveness of opioids in neuropathic pain is the
activation of glial cells (6, 61).We have previously showed in
both in vivo and in vitro studies that microglial inhibitor,
minocycline, enhances the effectiveness of selective MOR, NOR,
and KOR, but not DOR ligands under neuropathy (62, 63).
The minocycline acts as an inhibitor of microglial activation;
therefore, both morphine and buprenorphine effectiveness are
enhanced in a CCImodel. This lets us assume that C021 improves
opioid effectiveness by similar mechanism—for morphine, the
beneficial analgesic effect is probably related to MOR and KOR,
as in case of buprenorphine also with NOR—however, further
research is required. Moreover, it was previously shown that
minocycline delays the development of morphine tolerance
(28). Here, we observed that C021 had beneficial effects on
the development of morphine tolerance. Accumulating evidence
indicates that activated microglia and astrocytes release several
proinflammatory factors (e.g., IL-1beta, IL-18, iNOS, and CCL2)
in the spinal cord and thus increase pathological pain conditions
(7, 8, 14). It has already been shown that in healthy animals,
repeated morphine exposure causes the activation of microglia
and results in the upregulation of key proinflammatory cytokines,
which contributes to the sensitization of spinal neurons (64,
65). Based on our results showing strong elevation of IBA-
1 after nerve injury and no changes in the protein levels
of astroglial activation markers, microglia seems to be a
more important player. Previous immunohistochemical analyses
performed by our team (66) and others (67–71) visualized
the changes in microglial activation in the spinal cord. It
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has been previously demonstrated that after peripheral nerve
injury, activated microglial cells proliferate and change their
morphology from ramified to amoeboid, as well as increasingly
expressed markers such as IBA-1 (72). Interestingly, we did not
observe any significant changes in the levels of IL-1beta, IL-
18, or iNOS 12 days after nerve injury. However, it is known
from our previous studies that these factors are especially crucial
in the early phase of neuropathic pain development (14). On
the basis of our current studies, we cannot exclude that the
repeated administration of C021 influences these factors at
earlier time points; thus, further experiments are needed to
dispel these doubts. Moreover, recent studies have suggested
that CCL2 is a key mediator of spinal microglial activation
and is strictly involved in lower opioid effectiveness in naive
mice (73). Furthermore, CCL2 neutralization can enhance the
effectiveness of morphine in a mouse model of neuropathic pain
(25). Currently, we showed that blocking CCR4 simultaneously
to reduce the level of microglia/macrophage activation on the
12th day post-CCI prevents the upregulation of CCL2.
In addition to morphine, buprenorphine is widely used in the
clinic for chronic pain treatment. It was recently demonstrated
that the usage of CCL2 neutralizing antibodies enhances the
analgesic potency of buprenorphine in neuropathic mice (25);
therefore, we suggest that the potentiation of the antinociceptive
effects of buprenorphine after repeated C021 treatment might
also be associated with decreased levels of immune factors such
as CCL2. As we mentioned before, chemokine receptors are able
to form heterodimers with opioid receptors. It was previously
documented that both MOR and NOR independently drive
buprenorphine-induced analgesia in mice (74). In our study,
we demonstrated that buprenorphine is an effective analgesic
when administered for 12 days. However, after 5 days, it
slightly loses its antinociceptive potential, which remains at a
constant level; thus, we observed the known buprenorphine
“ceiling effect” (75). The results suggest that in the early phase
of neuropathy development, buprenorphine-induced analgesia
is probably associated with the activation of MOR and NOR.
However, in the late phase, NOR is primarily responsible for the
prolonged antinociceptive effects of this opioid because MOR
has already been observed to be downregulated in CCI-exposed
animals (76). Our data provide evidence for the first time that
CCR4 blockade increases opioid-induced analgesia and therefore
could be an innovative pharmacological cotreatment designed to
decrease hypersensitivity evoked by nerve injury. Additionally,
our results give first evidence that C021 significantly improves
the motor functions in neuropathic rats. In 2007, we have shown
that minocycline not only diminished neuropathic pain-related
behaviors but also improved the motor efficiency, which was
associated with silencing spinal microglial activation (34). It was
previously demonstrated that after peripheral nerve injury, not
only sensory neurons but also motoneurons are damaged, which
in turn implies strong activation of microglial cells in both the
dorsal and ventral horns of the spinal cord (71). Our current
results indicate that blockade of CCR4 by C021 beneficially
influences spinal microglial cell activation and probably as
a consequence improves the locomotor activity. Moreover,
relieving the pain through C021 administration certainly allows
animals to move freely, which can be also useful in accelerating
regeneration (77, 78).
In light of subsequent research, we propose that CCR4 is a
promising potential target for the pharmacotherapy of painful
neuropathy. Our data showed that C021 diminished tactile and
thermal hypersensitivity, improved motor function, and also
favorably impacted the effectiveness of opioids in a mouse model
of neuropathic pain. Because neuroimmune interactions are
important in the development of neuropathy and considering the
promising results obtained in our biochemical studies, we suggest
that the pharmacological blockade of CCR4 may represent a new
strategy for neuropathic pain polytherapy in the future.
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